Opinion Dr Kamala Maddali looks at how artificial intelligence is currently being utilized across the healthcare spectrum and why the time is now for Big Pharma to adopt this technology more fully. The beauty of artificial intelligence is that it allows one to assess both forest and tree. A…
China Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the complexities of attracting and retaining talent in the highly competitive Chinese market. In 2014, my first angel investor actually…
Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI. As Biopharma increases AI investments,…
Thailand Sumalee Kristarnin, country president of Novartis Thailand, shares the main initiatives of the affiliate in Thailand to take care of people, employees and patients. She highlights how the key priorities, put in place at the global level, are reflected in the local business, and how Novartis is trying to introduce…
Opinion Bayer’s Michael Levy examines how artificial intelligence (AI) can assist in both the routine and advanced analytical tasks involved in conducting pharmacovigilance and therefore better ensure the safety of pharmaceuticals and the health of patients. Pharmacovigilance or Patient Safety aims to promote and protect the health and well-being of…
Thailand Nares Damrongchai and Sirasak Teparkum from the Thailand Center of Excellence for Life Sciences (TCELS) lay out current challenges in the Thai healthcare and life sciences industry, their mains axes of research as well as how TCELS is helping the development of Thai startups and expanding international collaboration. Thailand…
Opinion Emanuele Ostuni, head of cell & gene therapy for Novartis Oncology in Europe, outlines how stakeholders across the biopharmaceutical value chain can surf the wave of innovation that breakthrough therapies such as CAR-T represent. Waves and Innovation CAR-T therapies are the frontrunners of a wave of amazing biomedical innovation Over…
China Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which is Old Norse for ‘to cure, to heal’. He also outlines Laekna’s focus on disease biology, specifically the areas of…
Cell & Gene Therapy Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as younger people with disabilities, has recently announced it will be increasing reimbursement rates and expanding coverage for cell and gene therapy treatments, good news for cancer patients and pharma companies Gilead…
Taiwan Lily Wu, CEO of PapiVax, discusses the biotechs initiative pipeline for the treatment of HPV related diseases and cancers and goes on to elaborate the company’s development and future partnership strategies. Wu also discusses the unique structure of PapiVax as a lean, R&D and research-driven biotech which is powered by…
Thailand As the general manager of Menarini Thailand, Thomas Scott Birsinger shares the importance of the Thai affiliate within the company’s operations in the region. He also describes its efforts to work closely with both the government and industry to help ensure access to the most crucial medicines across very diverse…
Sweden The Top 20 pharma companies in Sweden ranked by sales in 2018. Out in front is Swiss giant Novartis with approx USD 256 million in sales, followed by MSD with USD 220 million and Pfizer with USD 212 million. The companies with the highest levels of sales growth since 2017…
See our Cookie Privacy Policy Here